DHG Pharmaceutical Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
DHG Pharmaceutical has been growing earnings at an average annual rate of 9%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 6.7% per year. DHG Pharmaceutical's return on equity is 18.8%, and it has net margins of 16.2%.
Anahtar bilgiler
9.0%
Kazanç büyüme oranı
9.0%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 13.0% |
| Gelir büyüme oranı | 6.7% |
| Özkaynak getirisi | 18.8% |
| Net Marj | 16.2% |
| Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
DHG Pharmaceutical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 24 | 4,960,915 | 804,086 | 1,257,799 | 0 |
| 30 Jun 24 | 4,998,538 | 814,146 | 1,301,665 | 0 |
| 31 Mar 24 | 5,045,356 | 884,696 | 1,315,193 | 0 |
| 31 Dec 23 | 5,015,395 | 1,017,143 | 1,291,264 | 0 |
| 30 Sep 23 | 4,810,958 | 993,775 | 1,270,014 | 0 |
| 30 Jun 23 | 4,873,182 | 1,090,086 | 1,220,634 | 0 |
| 31 Mar 23 | 4,839,799 | 1,058,431 | 1,210,454 | 0 |
| 31 Dec 22 | 4,676,016 | 956,801 | 1,181,417 | 0 |
| 30 Sep 22 | 4,439,228 | 892,071 | 1,174,916 | 0 |
| 30 Jun 22 | 4,221,993 | 830,993 | 1,122,464 | 0 |
| 31 Mar 22 | 4,050,562 | 798,323 | 1,061,858 | 0 |
| 31 Dec 21 | 4,003,170 | 747,903 | 1,060,127 | 0 |
| 30 Sep 21 | 4,121,504 | 787,063 | 1,023,878 | 0 |
| 30 Jun 21 | 4,042,091 | 752,087 | 998,994 | 0 |
| 31 Mar 21 | 3,914,547 | 737,784 | 994,176 | 0 |
| 31 Dec 20 | 3,755,619 | 711,679 | 1,002,160 | 0 |
| 30 Sep 20 | 3,823,169 | 706,750 | 1,020,092 | 0 |
| 30 Jun 20 | 3,832,489 | 658,089 | 1,043,556 | 0 |
| 31 Mar 20 | 3,988,019 | 649,948 | 1,064,307 | 0 |
| 31 Dec 19 | 3,896,754 | 610,326 | 1,020,875 | 0 |
| 30 Sep 19 | 3,829,823 | 593,646 | 1,003,392 | 0 |
| 30 Jun 19 | 3,783,556 | 614,656 | 997,789 | 0 |
| 31 Mar 19 | 3,740,890 | 568,033 | 995,814 | 0 |
| 31 Dec 18 | 3,882,128 | 581,921 | 1,010,522 | 0 |
| 30 Sep 18 | 4,022,342 | 529,246 | 1,019,551 | 0 |
| 30 Jun 18 | 4,096,274 | 513,625 | 1,047,586 | 0 |
| 31 Mar 18 | 4,088,815 | 553,923 | 1,033,775 | 0 |
| 31 Dec 17 | 4,062,753 | 572,358 | 1,050,471 | 0 |
| 30 Sep 17 | 3,885,199 | 626,590 | 1,005,542 | 0 |
| 30 Jun 17 | 3,899,974 | 643,271 | 969,792 | 0 |
| 31 Mar 17 | 3,849,999 | 605,147 | 947,817 | 0 |
| 31 Dec 16 | 3,783,045 | 585,715 | 928,958 | 0 |
| 30 Sep 16 | 3,756,702 | 521,875 | 886,209 | 0 |
| 30 Jun 16 | 3,830,975 | 528,813 | 821,983 | 0 |
| 31 Mar 16 | 3,754,089 | 539,435 | 761,820 | 0 |
| 31 Dec 15 | 3,607,760 | 500,418 | 719,924 | 0 |
| 30 Sep 15 | 3,770,063 | 468,201 | 1,028,083 | 0 |
| 30 Jun 15 | 3,687,376 | 446,703 | 1,178,230 | 0 |
| 31 Mar 15 | 3,857,620 | 429,449 | 1,342,617 | 0 |
| 31 Dec 14 | 3,912,518 | 450,484 | 1,411,363 | 0 |
| 30 Sep 14 | 3,691,476 | 501,717 | 1,207,152 | 0 |
| 30 Jun 14 | 3,589,442 | 585,400 | 1,142,620 | 0 |
| 31 Mar 14 | 3,344,391 | 591,197 | 1,052,512 | 0 |
| 31 Dec 13 | 3,390,797 | 588,960 | 1,028,506 | 0 |
Kaliteli Kazançlar: DHG has high quality earnings.
Büyüyen Kar Marjı: DHG's current net profit margins (16.2%) are lower than last year (20.7%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: DHG's earnings have grown by 9% per year over the past 5 years.
Büyüme Hızlandırma: DHG's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Kazançlar vs. Sektör: DHG had negative earnings growth (-19.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-11.5%).
Özkaynak Getirisi
Yüksek ROE: DHG's Return on Equity (18.8%) is considered low.